FY2024 EPS Estimates for MediWound Lowered by HC Wainwright

MediWound Ltd. (NASDAQ:MDWD) – Stock analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of MediWound in a research report issued to clients and investors on Wednesday, November 27th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings of ($2.61) per share for the year, down from their previous forecast of ($2.14). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.47) per share. HC Wainwright also issued estimates for MediWound’s Q4 2024 earnings at ($0.54) EPS, Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.71) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.69) EPS, FY2026 earnings at ($1.87) EPS, FY2027 earnings at ($0.80) EPS and FY2028 earnings at $1.06 EPS.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the company posted ($0.24) EPS.

MediWound Stock Up 1.8 %

Shares of NASDAQ:MDWD opened at $18.42 on Monday. The firm has a 50 day moving average of $17.19 and a 200 day moving average of $17.39. The company has a market capitalization of $198.75 million, a price-to-earnings ratio of -6.35 and a beta of 0.81. MediWound has a 52 week low of $8.81 and a 52 week high of $24.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. MetLife Investment Management LLC purchased a new position in MediWound during the 3rd quarter worth $89,000. Rhumbline Advisers acquired a new position in shares of MediWound in the second quarter valued at about $131,000. Barclays PLC raised its stake in shares of MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 8,449 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in MediWound in the third quarter valued at approximately $212,000. Finally, Bank of New York Mellon Corp acquired a new position in MediWound in the 2nd quarter worth approximately $342,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.